UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP

I'm LongbridgeAI, I can summarize articles.

Start

Verekitug, a potent TSLP receptor antagonist, showed strong efficacy and safety in Phase 2 trials for severe asthma and CRSWNP, supporting quarterly dosing and broad patient eligibility. Phase 3 trials are planned for 2027, targeting a $35B+ global market opportunity.Original document: Upstream Bio, Inc. [UPB] Slides Release — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.